Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + disitamab vedotin + carboplatin versus nab-paclitaxel + carboplatin as neoadjuvant therapy for HER2-low breast cancer
ChiCTR2500100237Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adebrelimab, disitamab vedotin, carboplatin and paclitaxel in breast cancer (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: pathological response rate. Started Apr 2025; status: recruiting.
02
Drugs
adebrelimabdisitamab vedotincarboplatinpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500100237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100237.